Neudesin in obesity and type 2 diabetes mellitus: the effect of acute fasting and weight reducing interventions.
acute fasting
bariatric surgery
energy homeostasis
neudesin
obesity
type 2 diabetes mellitus
weight reduction
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
18
4
2019
Statut:
epublish
Résumé
Neudesin has recently been identified as a novel regulator of energy expenditure in experimental animals; however, its role in humans remains unexplored. The aim of this study was to assess the effects of obesity and type 2 diabetes mellitus (T2DM) along with selected weight reducing interventions on serum neudesin levels and adipose tissue mRNA expression. Fifteen obese subjects with T2DM undergoing endoscopic duodenal-jejunal bypass liner (DJBL) implantation, 17 obese subjects (11 with T2DM, 6 without T2DM) scheduled for gastric plication (GP), 15 subjects with functional hypoglycemia subjected to 72-hour acute fasting (AF), and 12 healthy controls were included in the study. Baseline neudesin levels were comparable between all groups. DJBL increased neudesin at 6 and 10 months after the procedure (1.77±0.86 vs 2.28±1.27 vs 2.13±1.02 ng/mL, Neudesin levels are differentially regulated during AF and chronic weight reduction induced by DJBL or GP. Further studies are needed to assess its possible significance in energy homeostasis regulation in humans.
Identifiants
pubmed: 30992678
doi: 10.2147/DMSO.S193259
pii: dmso-12-423
pmc: PMC6445223
doi:
Types de publication
Journal Article
Langues
eng
Pagination
423-430Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Nature. 2000 Apr 6;404(6778):661-71
pubmed: 10766253
Curr Treat Options Cardiovasc Med. 2001 Aug;3(4):323-332
pubmed: 11445062
Nature. 2001 Dec 13;414(6865):799-806
pubmed: 11742412
Circulation. 2002 Jul 16;106(3):286-8
pubmed: 12119239
J Neurosci Res. 2005 Feb 1;79(3):287-94
pubmed: 15605373
Biochem Biophys Res Commun. 2009 Mar 27;381(1):75-80
pubmed: 19351598
BMC Cancer. 2012 Jul 02;12:274
pubmed: 22748190
Curr Protein Pept Sci. 2012 Nov;13(7):687-96
pubmed: 23228349
Am J Physiol Regul Integr Comp Physiol. 2013 Jun 15;304(12):R1085-95
pubmed: 23576617
Front Neurosci. 2013 Jun 25;7:111
pubmed: 23805070
Front Behav Neurosci. 2013 Sep 09;7:119
pubmed: 24058337
Lancet Diabetes Endocrinol. 2014 Feb;2(2):152-64
pubmed: 24622719
J Endocrinol. 2014 Oct;223(1):T63-70
pubmed: 25232148
Front Neurosci. 2014 Oct 13;8:313
pubmed: 25352770
Pharmacoeconomics. 2015 Jul;33(7):673-89
pubmed: 25471927
Sci Rep. 2015 May 08;5:10049
pubmed: 25955136
Front Mol Biosci. 2015 May 19;2:24
pubmed: 26042224
Endocrine. 2015 Nov;50(2):276-91
pubmed: 26089260
Diab Vasc Dis Res. 2017 Jul;14(4):277-284
pubmed: 28423914
J Endocrinol. 2018 Apr;237(1):R1-R17
pubmed: 29378901
BMJ. 1997 Mar 29;314(7085):955-9
pubmed: 9099123